All In Biotech

Drug Trial Radar · NCT07856511

A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Proximod Tablets in Moderate-to-Severe Active Rheumatoid Arthritis Subjects With Inadequate Response or Intolerance to bDMARDs and/or tsDMARDs

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Apr 1, 2027

Study completion Sep 30, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs

Conditions

  • Rheumatoid Arthrits

Interventions

  • PlaceboDrug

    The placebo group will take drugs orally for 16 weeks, and then were randomly assigned to proximod dose 1 and proximod dose 2 for 36 weeks, in the meanwhile, proximod dose 1 group and proximod dose 2 group will continue taking drugs for the whole 52 weeks.

  • ProximodDrug

    The placebo group will take drugs orally for 16 weeks, and then were randomly assigned to proximod dose 1 and proximod dose 2 for 36 weeks, in the meanwhile, proximod dose 1 group and proximod dose 2 group will continue taking drugs for the whole 52 weeks.

  • ProximodDrug

    The placebo group will take drugs orally for 16 weeks, and then were randomly assigned to proximod dose 1 and proximod dose 2 for 36 weeks, in the meanwhile, proximod dose 1 group and proximod dose 2 group will continue taking drugs for the whole 52 weeks.

  • PlaceboDrug

    The placebo group will take drugs orally for 16 weeks, and then switch to proximod for 36 weeks, in the meanwhile, proximod group will continue taking drugs for the whole 52 weeks.

  • ProximodDrug

    The placebo group will take drugs orally for 16 weeks, and then switch to proximod for 36 weeks, in the meanwhile, proximod group will continue taking drugs for the whole 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACR20 response rate at week 16(Phase I and Phase II)Time frame: Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.